The table below shows AbCellera Biologics Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Revenue
$75.13M
$28.83M
$38.02M
$485.42M
$375.20M
$233.16M
Cost of revenue
-
-
-
-
-
-
Gross profit
-
-
-
-
-
-
R&D
$186.83M
$167.26M
$175.66M
$107.88M
$62.06M
$29.39M
SG&A
ABCL annual revenue (10-K history)
AbCellera Biologics Inc. reported annual revenue of $75.13M for fiscal year 2025. That is up 160.6% from $28.83M in fiscal 2024. Over the 7 fiscal years shown, annual revenue grew from $11.61M (FY 2019) to $75.13M. Figures come from the company's audited annual reports as filed with the SEC.
